Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach

BackgroundNo biomarker was identified for gastric GISTs(GG) detection. We first observed that glands surrounding GG are regionally atrophic. We hypothesize that this local atrophy may mildly reduce pepsinogen Ⅰ(PGⅠ) but the PGⅠ/PGII ratio remains normal. To test our hypothesis, a retrospective analysis was conducted to evaluate the diagnostic efficiency of PG in GG detection.MethodsWe retrospectively analyzed a cohort of consecutive GG and gastric cancer(GC) patients at our center. Pathologic confirmed GG patients and GC patients with tested PG levels before medical intervention were included. Three criteria were assessed: 1.Serum PGI≤70ng/ml; 2.Positive-Gastric-GIST-PG(PGⅠ≤70 ng/ml and PGI/PGII ratio>3.0); and 3.Positive-Gastric-GIST-PG-CEA(Positive-Gastric-GIST-PG plus normal CEA). Sensitivity, specificity, positive predictive value(PPV), negative predictive value(NPV) and overall accuracy(OA) were calculated. A Chi-square test was applied to detect the differences.ResultsAfter screened 562 GG and 1090 GC, 100 GG and 174 GC samples were included. For PGI≤70ng/ml, the Positive-Gastric-GIST-PG and the Positive-Gastric-GIST-PG-CEA criteria discriminating GG from GC, the sensitivities were 75%(95%CI 66-82),70%(60-78) and 68%(58-76), respectively; the specificities were 50%(43-57), 70%(62-76), and 78%(71-83), respectively; the PPV were 46%(39-54), 57%(48-65), and 64%(55-73), respectively; the NPV were 78%(69-84), 80%(73-86), 81%(74-86), respectively; and the OA were 59%(53-65), 70%(64-75), and 74%(69-79), respectively. There was statistic difference in sensitivities between GG and GC for Positive-Gastric-GIST-PG-CEA criterion(68% for GG vs. 22% for GC, P<0.0001). ConclusionSerum PGs are useful for both detecting GG and distinguishing GG from GC. Integrating our criteria into current PG test scheme of gastric precancerous screening will be helpful for early GG detection without additional economic expense.

[1]  Leping Li,et al.  [Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study]. , 2017, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.

[2]  Shan Wang,et al.  The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors , 2017, BMC Gastroenterology.

[3]  J. Sicklick,et al.  Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA , 2016, Journal of Gastrointestinal Surgery.

[4]  Seiichi Hirota,et al.  The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines , 2015, Gastric Cancer.

[5]  U. Guller,et al.  Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis , 2015, Gastric Cancer.

[6]  J. Sicklick,et al.  Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[7]  Ying Zheng,et al.  Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010 , 2014, Gastroenterology research and practice.

[8]  K. Chayama,et al.  Advanced Method for Evaluation of Gastric Cancer Risk By Serum Markers: Determination of True Low‐Risk Subjects for Gastric Neoplasm , 2014, Helicobacter.

[9]  PhD Kazuyoshi Yamamoto MD,et al.  Impact of the Japanese Gastric Cancer Screening System on Treatment Outcomes in Gastric Gastrointestinal Stromal Tumor (GIST): An Analysis Based on the GIST Registry , 2014, Annals of Surgical Oncology.

[10]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[11]  Wei-Chih Liao,et al.  Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors. , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[12]  P. Went,et al.  Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study. , 2011, Human pathology.

[13]  K. Miki Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method” , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[14]  D. Park,et al.  Current Trends in the Epidemiological and Pathological Characteristics of Gastrointestinal Stromal Tumors in Korea, 2003-2004 , 2010, Journal of Korean medical science.

[15]  M. Fujishiro,et al.  Cautious comparison between East and West is necessary in terms of the serum pepsinogen test , 2009, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[16]  A. Hartmann,et al.  Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.

[17]  T. Nakajima,et al.  High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.

[18]  Xianghong Zhang,et al.  [Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma]. , 2006, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[19]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[20]  L. Koniaris,et al.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. , 2006, Journal of the American College of Surgeons.

[21]  R. Herings,et al.  Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. , 2005, European journal of cancer.

[22]  H. El‐Serag,et al.  The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.

[23]  C. Ball,et al.  The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. , 2004, The American journal of pathology.

[24]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[25]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[26]  R. Newcombe Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.